RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its
subsidiary BioSyent Pharma Inc. has launched Cathejell(TM) Jelly 2% a Sterile
Topical Anesthetic for the Canadian healthcare market.


Cathejell(TM) Jelly 2% is an innovative pharmaceutical product that combines a
sterile gel and lidocaine in a unique collapsible applicator syringe which
provides a safe and effective solution for patients to ease the discomfort of a
range of medical procedures. Cathejell(TM) Jelly 2% is indicated for surface
anesthesia and lubrication for various procedures including: male and female
cystoscopies, catheterizations and other endourethral operations; endoscopies,
proctoscopies, rectoscopies; and tracheal intubations. Cathejell(TM) Jelly 2%
can also be used for the symptomatic treatment of pain in connection with
cystitis and urethritis.


Cathejell(TM) Jelly 2% was in-licensed by BioSyent Pharma from Pharmazeutische
Fabrik MONTAVIT of Absam, Austria (MONTAVIT) and was approved by Health Canada
in July 2011 (DIN 02370840). MONTAVIT has been producing and successfully
marketing Cathejell(TM) Jelly 2% for over 40 years. Cathejell(TM) Jelly 2% is
used by healthcare professionals in hospitals and clinics in over 50 countries
around the world including England, Germany, France, Switzerland, Sweden, Italy
and Spain.


Cathejell(TM) Jelly 2% has a unique collapsible syringe design with a
trauma-free applicator tip that makes it easy to use for healthcare
professionals and makes the application of the drug more comfortable for the
subject patient.


Cathejell(TM) Jelly 2% is now available to all hospitals, pharmacies and urology
clincs across Canada. Shipments for Cathejell(TM) Jelly 2% will commence in May
2012. For more information regarding Cathejell(TM) Jelly 2% visit
www.cathejell.ca.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada. The
Company is focused on medications that occupy a niche in the market, that are
unique either due to complexity of manufacture or provide novel technological or
therapeutic advantages, or that are backed by strong partners holding
intellectual property rights that are defendable. This strategy allows the
Company to market these medications as brands owned by, or licensed to, it.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX. 


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024